Tempest Therapeutics (TPST) Share-based Compensation (2012 - 2026)
Tempest Therapeutics (TPST) posted Share-based Compensation of $576000.0 for Q4 2025, up 844.26% sequentially from $61000.0 in Q3 2025, and down 56.72% YoY from $1.3 million in Q4 2024.
Tempest Therapeutics (TPST) Share-based Compensation (2012 - 2026) Analysis & Trends
Tempest Therapeutics has reported Share-based Compensation for 14 years, with the latest figure at $576000.0 in Q4 2025.
- Quarterly Share-based Compensation fell 56.72% year-over-year to $576000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (down 41.2% YoY) and the FY2025 annual result came in at $3.1 million, down 41.2% from the prior year.
- Share-based Compensation rose to $576000.0 in Q4 2025 per TPST's latest filing, from $61000.0 in the prior quarter.
- Over five years, Share-based Compensation peaked at $9.5 million in Q4 2022 and troughed at -$778000.0 in Q4 2021.
- A 5-year average of $1.1 million and a median of $504500.0 in 2023 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2021 and 2022: Share-based Compensation tumbled 142.37% in 2021, then surged 1324.55% in 2022.
- Over 5 years, Share-based Compensation stood at -$778000.0 in 2021, then soared by 1324.55% to $9.5 million in 2022, then tumbled by 88.49% to $1.1 million in 2023, then increased by 21.33% to $1.3 million in 2024, then sank by 56.72% to $576000.0 in 2025.
- According to Business Quant data, Share-based Compensation over the past three periods registered $576000.0, $61000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Tempest Therapeutics | 4.23 Mn | 3.43 Mn | - | -119,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -119,000.00 |
| Jun 30, 2026 | -119,000.00 |
| Dec 31, 2025 | 576,000.00 |
| Dec 31, 2025 | 576,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Sep 30, 2025 | 61,000.00 |
| Jun 30, 2025 | 1.09 Mn |
| Jun 30, 2025 | 1.09 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Dec 31, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Sep 30, 2024 | 1.33 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Jun 30, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Mar 31, 2024 | 1.32 Mn |
| Dec 31, 2023 | 1.10 Mn |
| Dec 31, 2023 | 1.10 Mn |